Dr. Amit Etkin is pioneering a revolution in the way mental health medications are designed, developed, prescribed, and brought to market.  Precision psychiatry is the future of mental health treatment and Dr. Etkin is leading the way with his drug development platform, Alto Neuroscience.  In this episode, Dr. Etkin explains why psychiatric drugs have failed, what he is doing about it and why it will work.  Prior to Alto Neuroscience, Dr. Etkin was a tenured professor in the Department of Psychiatry and Behavioral Sciences at Stanford University and a member of the Wu Tsai Neurosciences Institute. Dr. Etkin has received multiple awards, most notably the NIH Director’s Pioneer Award in 2017. He is trained as both a psychiatrist and neuroscientist. The overarching aim of his work in this field for the last 10 years is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions. In support of this goal, Dr. Etkin also collaborates with neuroscientists, engineers, psychologists, physicians, and others to establish a new intellectual, scientific, and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease. You can connect with Amit here:  LinkedIn Alto Neuroscience Website: https://www.altoneuroscience.com/ What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Etkin shares his background, why he got into the field of neuroscience, and why he is building Alto Neuroscience. We discuss the biggest needs in the clinical psychology world is and how Alto Neuroscience will solve some of the greatest needs in the mental health space. We talk about measurement & testing, as well as biomarkers in the mental health space at large and why we are so far behind other healthcare verticals when it comes to measurement and testing in the mental health space. Etkin explains that one of the primary reasons bio-pharma companies haven’t focused as much as they should on Central Nervous System (CNS) drug development in the last couple of decades is because we can’t effectively measure how the drugs are working. All of that has changed now with the creation of Alto Neuroscience.  Amit talks about the concept of “precision psychiatry”, how precision is utilized in other fields of medicine, and the importance of using it in the mental health space to improve treatment options. We discuss how the combination of measurement and precision psychiatry can change psychiatry, drug development, and treatment of mental health disorders both broadly on a macro level and specifically with respect to his work at Alto Neuroscience. Amit shares about what Alto Neuroscience is currently working on, the drugs they currently developing, and their vision for the future of psychiatric medication.   Connect with the Stigma Podcast in the following ways: Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

Stigma Podcast - Mental Health

#89 - The Future of Precision Psychiatry with Dr. Amit Etkin of Alto Neuroscience

Amanda Eilian, Founding Partner of _able Partners joins us to talk all things mental health startup investing. _able Partners is an early-stage VC firm supporting visionary founders in the positive living space. Their investments focus on companies that improve the daily lives of people, making them healthier, happier, and making their lives more meaningful. Some specific investment areas include mental health, addiction, women’s health, sexual wellness, wellness broadly, coaching and continued learning, child care, and self-expression. Amanda has led incredible early stage investments in companies like Spring Health, Compass Pathways, ATAI Life Sciences, Alma, Alto Neuroscience, and many others. You can connect with Amanda here:  _able Partners Website, LinkedIn What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Amanda shares her background that led her to venture investing, creating _able Partners, and the focus of _able Partners. We discuss the areas and companies where _able has focused on which have been stigmatized in the past including mental health and addiction. Amanda shares about her team, how they are non-traditional, and what that looks like in terms of their professional interactions as a company. We discuss current themes in the mental health space and where investors should be looking to get involved in this space including accessibility, personalized care, and measurement and monitoring. Amanda shares what type of funding _able is interested in, their focus in early stage investing, and what criteria they look for when choosing who to work with. We talk about why stigma is starting to decrease and the possible causes for this wave of de-stigmatization. We discuss the lack of access, the shortage of psychiatrists across the country, and more issues surrounding mental health care and Amanda shares her ideas for what needs to happen to address these issues.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#88 - _able Partners Founding Partner Amanda Eilian - A Pioneer in Mental Health Investing

Today’s guest is John Donoghue. He is well known for his groundbreaking work developing Brain Computer Interfaces (BCIs) to restore movement for people with paralysis, known as ‘BrainGate’. BrainGate was the original BCI system created by a company called Cyberkinetics, of which John was a co-founder. In this episode, John gives us a primer on BCIs.  What are they? How do they work? When will they be widely adopted?  Are they safe?  How do we know?  We cover these questions and much more. Many people consider John to be the founder of the entire discipline of neuroprosthetics which is the combination of neuroscience and biomedical engineering. He was a member of the U.S. B.R.A.I.N. initiative’s first NIH Working Group and is a fellow of the National Academy of Medicine, American Academy of Arts and Sciences, as well as several other academies. His awards include the German Zülch Prize (2007), the Roche-Nature Medicine Prize (2010), the Schrödinger Prize (Germany, 2012), and the first Israeli Brain Technology Prize in 2013. Links Mentioned:  BrainGate Website, John’s email What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: John shares his background in biology, his fascination with the way our brains control and plan movement which ultmiately led him to explore how we can use computers to restore that functionality via Brain Computer Interfaces (BCIs) one day. John has spent more than 30 years focused on the potential of using BCIs to solve some of the most debilitating physical ailments that humans face. In this conversation, John gives an in-depth explanation of what a BCI is, how it works, the different types that are available, and the variety of uses that can come from each type. We discuss where BCIs started in the early 2000’s in human trials, the advancement of the technology since then and where we are today. John shares how he sees this technology being used on a larger scale, what is currently holding it back, and what it will take to get it to be used in more humans in the coming years. John shares where he thinks the opportunities are for entrepreneurs in this space and how to get involved in this technology and transform it for more uses. We discuss the ethical considerations around reading brain signals and using computers to send signals back to the brain telling it how to move the body and eventually, adjusting how people think and feel.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#87 - Brain Computer Interfaces - A Primer with John Donoghue

Today’s guest is Elyse Cohen, VP of Social Impact and Inclusion at Rare Beauty by Selena Gomez and a mental health advocate.  Elyse is an expert on purpose driven brands, social impact, and has been hand selected by Selena Gomez to lead the impact efforts at Rare Beauty and the Rare Impact Fund addressing mental health. Previously Elyse has worked at the White House for First Lady Michelle Obama as Deputy Director of the former first lady’s legacy Let’s Move initiative, the U.S. Chamber of Commerce Foundation, and various marketing agencies leading social impact initiatives and leveraging business and celebrity assets to create change on critical issues. You can connect with Elyse here:  LinkedIn Links mentioned in the show: GoFundMe, Rare Beauty Website What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: We talk about Rare Beauty as a purpose driven brand, The Rare Impact Fund which addresses access and gaps in mental health, and the growth of the brand over time. We also discuss ways for people to get involved with the growth of the Rare Impact Fund. Elyse shares her background, both personal and professional, and why mental health is so personally important to her and her family. As part of her work, Elyse has mapped out who is doing what, and who is being impactful in the mental health space for the purpose of knowing where to deploy Rare Impact Fund capital. Elyse shares some of the insights she gained by doing that work including which companies are doing great work in the mental health space and where she wants to see capital deployed. We discuss barriers to mental health care including stigma, cost of care and access in our current system, and what we need to do to address the issue of stigma around mental health. Elyse shares about what the Rare Impact Fund plans to do with the capital that is raised and what benefits will come from these actions. We discuss the lack of practitioners, why there is such a deficit in this field, and what changes could be made to fill the gap. Elyse talks about the white space that still exists in mental health especially in education and technology, and why filling these spaces with more support will be beneficial in the long term.   Connect with the Stigma Podcast in the following ways: Website, Twitter, Facebook, LinkedIn, Email, What If Fellowship Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#86 - Elyse Cohen - VP Social Impact at Rare Beauty by Selena Gomez

You can’t fix what you don’t measure.  Measurement and testing of our mental health lags the same capabilities in physical health care.  Dr. Nick Allen, our guest today, is building a mental health measurement solution for clinical use.  Today we talk to him about the challenges, and opportunity for his startup, Ksana Health. Nick is leveraging the tools and technologies that he developed as the Director of University of Oregon’s Center for Digital Mental Health into products and services that are transforming mental health care. Nick is a clinical psychologist and social neuroscientist who investigates the interaction between biological, psychological, and environmental risk factors during adolescent development and measures these factors to focus on prevention of mental health problems. You can connect with Anthony here on LinkedIn: https://www.linkedin.com/in/nick-allen-42256218a/ Ksana Health website:  https://ksanahealth.com/ What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Nick shares his background in psychology, his focus on adolescent mental health, and about his decision to build Ksana Health starting in 2019. We talk in depth about Ksana Health, how the technology effectively measures mental wellbeing on a continuous basis, and where they are with the platform today. Nick talks about the type of data that is being collected through Ksana Health, what this data is indicative of in terms of mental health, and what clinicians can do with this data to further treat their patients. We talk about what is coming next for Ksana Health post fundraising, two big projects that they are currently pursuing, and what benefits will come from these expansions to the company. Nick shares about which groups they are most interested in working with, why these groups fit with their current business model, and how it will lead to less crisis in mental health overall. We discuss the previous attempts at digital phenotyping, why it did not work as well in the past, and how Ksana Health is doing it more efficiently. Nick gives advice for those who are just starting to explore this space as investors and entrepreneurs, and what other opportunities are out there for people to get involved in who are interested in this space.     Connect with the Stigma Podcast in the following ways:  Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#85 - Measuring Mental Health with Ksana Health Co-Founder Nick Allen

Dr. Anthony Hassan, President and CEO of the Cohen Veterans Network (CVN) joins us today.  CVN is a network of 25 non-profit mental health clinics providing care to veterans and their families.  The facilities are located in or around historically dense veteran and active duty military communities. Dr. Hassan is a veteran of the United States Army and Air Force with 30 years of experience in military behavioral health. He holds a Doctorate in Higher Education Administration from the University of South Florida and is an alumnus of the Harvard Business School. You can connect with Anthony here:  Cohen Veterans Network, Email What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Anthony Hassan talks about his 30 years of experience in the military, focusing on the mental health of active-duty service members. We discuss the unique problems military members and veterans face regarding mental health and why finding help isn’t easy. We discussed the stigma around mental health specifically in the military and veteran communities and why it seems to be worse at times than in other communities. Anthony explained what mental health care services are in place for veterans, and where the gaps exist today and how the Cohen Veteran Network was created to fill those gaps. We talk about the workforce inside the clinics, the shortage of mental health workers in America, and how the Cohen Veterans Network fosters their network of clinicians on staff. The Cohen Veterans Network is continually experimenting with new technological advances and cutting-edge treatments that they believe can help veterans with their mental health. The CVN platform has become an incubator or pilot partner of choice for many up-and-coming technologies serving the mental health space. Anthony shares what the long-term goals are for the clinics and what is needed in terms of support to make those goals a reality.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#84 - Veterans Mental Health with Dr. Anthony Hassan, CEO of Cohen Veterans Network

Today’s guest is Jon Kostakopoulos who was the first study participant in the NYU Psilocybin clinical trial. After years of struggling with alcoholism and after trying other options including in-patient programs, out-patient programs, AA, and pharmaceutical treatments, nothing was working for him. Finally, at age 25, Jon joined the clinical trial and underwent three different Psilocybin treatment sessions and has not craved alcohol since his first treatment session. Jon has been interviewed on 60 minutes by Anderson Cooper regarding his Psilocybin treatments and since then has launched the Apollo Pact which is a non-profit funding medical research for mental health. You can connect with Jon here:  Email, Apollo Pact Website What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Jon shares about his struggles with alcoholism, early signs that showed his irregular relationship with alcohol, and how addiction impacted his life. We discuss the time put into his recovery and all the different options he attempted to get sober from ages 16-25. Jon shares how he learned of the clinical trial at NYU, the screening process, time leading up to the beginning of the trial and what the user experience was like for him. Jon goes into depth about the process of the clinical trial, what therapy was like before and after each Psilocybin experience, and what the aftermath was like during his year in the trial. We discuss the effectiveness of psilocybin in treating mental health issues and how it works by getting to the root of the problem with a wide variety of mental and behavioral health disorders. Jon shares about the work he is doing in the mental health space with Apollo Pact and how to get involved with this program. We talk about reasons why we think the government is not providing more support to these solutions when the efficacy is high, what needs to happen to finally get that support, and the unseen benefits for the government. We discuss the potential timeline for psilocybin to be more of a mainstream treatment with Oregon leading the way.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#83 - Psychedelic Treatment Cured My Alcohol Addiction - Jon Kostakopoulos

Today’s guest is Dan Housman. He’s the co-founder and CTO of Courage Therapeutics. We met Dan when he came through our first cohort of the What If Fellowship Program. His startup is a biopharma drug development business focused on eating disorders (anorexia nervosa specifically).   You can connect with Dan here: LinkedIn, Courage Therapeutics Website Links mentioned in the show: NEDA, Feast, Daniel Le Grange Research What If Fellowship Program: https://whatif.vc/   HERE ARE SOME THINGS WE TALKED ABOUT Dan tells us about the history of Courage Therapeutics and why his personal experience surrounding eating disorders inspired him to use his background in molecular biology to find a solution to this problem. We discuss the state of the market and current solutions available for eating disorders. Dan shares some of the reasons that he believes these current treatments only do so much. We discuss the drug that he has been working on developing, the effects that it is meant to have on those who struggle with anorexia, and Dan shares his hope that it can help to reduce the need for more severe treatment options. We talk about where Courage Therapeutics is at in the drug development timeline and what the next steps are to make sure that this drug will work and that it will be available as soon as safely possible. We discuss the statistics around eating disorders, specifically anorexia nervosa, and what this problem looks like in the United States, but also globally. Dan also shares that it’s not about how big the numbers are that necessarily make a product successful. There are many contributing factors. Dan shares about the stigma that surrounds eating disorders and why people are feeling unable to talk about them more. Dan shares resources for those who are interested in knowing more about eating disorders, who want to find resources to help themselves or a loved one who may be struggling with anorexia, and for general research papers around the topic itself. Connect with the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)  

#82 - Eating Disorders - Prevalence, and Lack of Solutions with Courage Therapeutics Founder Dan Housman

Today’s guest is Ali Abramovitz. She is the co-founder of Chorus Meditation and she is here to talk about the work she is doing to make meditation a group activity. In this episode, we will talk about why group meditation is beneficial, how to do it, and what exactly the benefits are.   You can connect with Ali here: Linked In, Chorus Website, Facebook, Instagram What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Ali shares about her background in business and as an investor, and how her own personal journey with meditation led her to create Chorus Meditation. We discuss the stigma around meditation, what roadblocks exist for traditional meditation, and how Chorus is finding ways around these roadblocks. Ali shares the ideas behind making meditation a group activity, the story of their development of Chorus, and how making meditation a shared experience benefits an individual. We discuss the power of shared experiences and how it changes the mindset of the individuals involved, and the resulting relationships that can form from this. Ali shares that the main problem they’re helping with is stress and how stress can affect your life and relationships. We discuss how the group dynamic has changed since the pandemic, the changes that were made to Chorus, what changes had to occur to continue to bring these benefits to people, and what the user interface looks like post-pandemic. We discuss where Ali sees Chorus going in the long run and what goals they have for the company. Finally, Ali shares her final thoughts on consistency being the key to real change and how Chorus can help everyone.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#81 - Is Meditation Really Hard? - with Chorus Meditation Founder Ali Abramovitz

Sean McBride, VP Partnerships at Lyra Health joins us in this episode to talk about Lyra, behavioral health care broadly, and he experience working to reform the healthcare system throughout his career.  Sean was the first employee at Lyra Health and shares with us about how the Company has scaled into a unicorn over the last 6 years.  Lyra Health is focused on making behavioral health care more accessible and easier to find.  Prior to Lyra, Sean worked at Castlight Health, The White House’s National Economic Council, and The Brookings Institution’s Health Care Reform Center among other positions. You can connect with Sean here: LinkedIn What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Sean shares his background in the healthcare industry, how it led him to Lyra Health, and his personal struggles with mental health. We discuss what Sean thinks is the thing keeping employees from using the tools that their employer provides and what an employer can do to create a supportive culture in the workplace. We talk about value-based care, what it is, and if we are moving in that direction in our system. We discuss the need to get our society to focus on our mental health and make it more of a priority like our physical health. Sean shares about Lyra Health, who they are, what they do for companies that they work with, and what benefits the employees get from an employer who works with Lyra. We discuss what Lyra Health looked like in the early days and how the objective of the company remains the same since then. Sean shares what he thinks is the ideal partner or customer for Lyra and what their marketing strategy looks like to reach this ideal audience. Finally, Sean gives his opinion on where he sees the most opportunity for aspiring entrepreneurs who are just starting out in this space and where the problems that need to be fixed are. Connect with the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)    

#80 - Lyra's VP of Partnerships (employee #1) - Sean McBride

In this episode, we are talking about entrepreneur mental health.  Our guest, Matthew Cooper, stepped down from his role as CEO of EarnUp after growing the business successfully for 7 years after creating it.  When he stepped down, he cited mental health as the primary driver and wrote an incredibly authentic, vulnerable and amazing blog post about his decision on December 18, 2020. You can connect with Matthew here: Blog, Twitter, Linked In What If Fellowship: https://whatif.vc/fellowship   HERE ARE SOME OF THE THINGS WE TALKED ABOUT: Matthew shares his story about his history of mental illness and how it led him to the place that he is at today in both his personal life and his career. We talk about the stressors that come with starting a business and how certain beliefs can lead to a feeling of isolation while being successful at the same time. We discuss what options are available for real support to entrepreneurs and founders of companies to prevent a mental health emergency or burnout. Matthew shares what tools he has tried and what worked for him, his experiences with in-patient treatments, and his mental health cycles that he has gone through. We discuss how mental health is not a linear journey for many people and how worth it it is to keep trying to find the right solution to your problem. We talk about what we can be doing to better support entrepreneurs as an ecosystem of founders and investors, but also as friends or family members of entrepreneurs. Finally, Matthew shares that human connection with safe people is a huge factor in keeping your mental health in a positive space as well as just sharing your story and being open with where you’re at mentally. Connect with the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)    

#79 - Matthew Cooper on Stepping Down as CEO for His Mental Health

In this episode we chat with long time healthcare startup investor, Esther Dyson.  Esther has been very influential in the healthcare investing space for quite some time.  It’s very hard to run into anyone doing anything meaningful in the broader healthcare space and not find a connection to Esther in some way. She’s the executive founder of Way to Wellville, a non-profit dedicated to demonstrating the value of investing in health, including how the benefits of investing in health accrue over time and not always to the investors directly. Esther spends her time investing in startups, a lot of them in the health space, and she is a board member at a bunch of companies such as 23&Me, Meetup, Yandez, as well as being an early investor in Square and many others. You can connect with Esther here: LinkedIn, Twitter, Wellville Website What If Fellowship Program: https://whatif.vc/fellowship   HERE ARE SOME THINGS WE TALKED ABOUT: Esther shares how she found her way into the mental health space as an investor and as an advocate encouraging more people to invest in the space. We talk about the difference between short-term and long-term thinking regarding health solutions and how society needs to decide to invest in better health overall rather than focusing on only the individual. Esther shared her opinion on what is actually beneficial to making a healthier society. It’s not what is being focused on now because we are too busy focusing on the short-term solutions. There’s a disconnect between the number of people who want to fix the healthcare problems and the money that is actually being put towards the solutions. Esther shares why she thinks there is a disconnect and what can be done about it. We discuss the wide range of the meaning of the word addiction and how it is not a moral failing, but rather a learned behavior. Esther shares what early investors should be looking for when choosing which companies to invest in to avoid investing in predatory companies and how to evaluate your investing opportunities to find the right one for you. We talk about what is the most important problem to focus on in the health space and how your personal mission affects your opinion on which problems are the main priority. We talk about the effect that the poor educational system is having on our country and how fixing the health issues around kids in school will hopefully lead to a better future with a healthier society with better access to care.   Connect with the What If Ventures and the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email   Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)  

#78 - Esther Dyson: Building a Healthier Society by Investing in Healthcare Startups

In this episode we speak with Dr. Errol De Souza, PhD, Executive Chairman of the Board of Directors at Bionomics.  Bionomics just raised nearly $16mm to conduct clinical trials on their revolutionary drug to treat PTSD.  Dr. De Souza is one of the premier entrepreneurs in the biotech space with a special focus on development of therapeutics for treatment of Central Nervous System disorders. During his career as an entrepreneur, Dr. De Souza has raised several hundred million dollars in capital in both private and public markets and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck). Over Dr. De Souza's career, he has served in a number of high-ranking R&D roles, including SVP and U.S. head of Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992). Dr. De Souza is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences (CBIO). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).  HERE ARE SOME OF THE THINGS WE TALKED ABOUT: De Souza shares his background and how it led him to the biopharmaceutical industry. We discuss what goes into the process of developing a drug for the Central Nervous System and ways that this process is the same and different from the development of other pharmaceuticals. De Souza discusses the two categories of disorders that come from the Central Nervous System, psychiatric and neurological, and the drug development history of the two dating back to the 50’s. We talk about the story behind Bionomics, their new compound BNC210 which is used for the treatment of PTSD which received a “Fast Track” designation from the FDA. De Souza helps us break down exactly what is PTSD, how it occurs, what’s going on in the brain and talks about how we can use that knowledge to develop biopharmaceutical treatments for PTSD (which is what Bionomics is leading the way on right now). He talks about current PTSD treatments and their shortcomings as well. We talk about the Bionomics collaboration with Merck which uses similar compounds in the clinical treatment of cognitive deficits in Alzheimer’s disease and why there are similarities between Alzheimer’s and PTSD based on the neurochemistry of the brain. Finally, Dr. De Souza gives some advice for entrepreneurs who are starting out early in their career and investors that are coming into this space who lack the background knowledge. Connect with the Stigma Podcast in the following ways: Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)    

#77 - Central Nervous System Drug Development with Industry Expert Dr. Errol De Souza (Chairman @Bionomics)

In this episode, we chat with Doug Drysdale, CEO of Cybin.  Cybin, is a life sciences company advancing mushroom based psychedelic pharmaceuticals and non-psychedelic nutraceutical products as potential therapies for psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aimed at improving bioavailability to achieve the desired effects of psychedelics at low dosage levels.  Doug is an extremely accomplished and experienced CEO who has chaired a NASDAQ-listed company and has built and turned around 3 different pharmaceutical companies over the last 12 years.  He has more than 30 years of experience in the healthcare sector broadly and brings a level of expertise to the psychedelics space that is truly incredible. You can connect with Doug here: LinkedIn, Doug’s website, Cybin website Links mentioned in the show:Press Release:  Cybin Completes Reverse Take-Over Transaction Benzinga Article: Cybin Corp: Canada’s Largest Go-Public Financing in the Psychedelics Sector Forbes Article: Pharmaceutical Startup Developing Sublingual Psilocybin Raises $34 Million to Fund Clinical Trials What If Fellowship Program: https://whatif.vc/fellowship   HERE ARE SOME THINGS WE TALKED ABOUT Doug tells us about his 30 years of experience in the healthcare field and how it led him most recently to the psychedelics space. Doug shares that his experience working in a hospital lab gave him the motivation to begin work in the mental health field. In his time in the ER, he shares that he saw many teenage suicide attempts and drug overdoses. Like so many of us, his personal connection to depression and addiction is another contributing factor to wanting to work in this space. We discuss how the pandemic has affected the psychedelic space and how mental health issues have been elevated through recent events. We talk about the speed at which psychedelics are growing as a treatment for mental health differences and whether or not it this growth, and the ensuring hype are sustainable or not. Doug explains that while it may seem that psychedelics are this “new solution” that these treatments have been around for more than 50 years, but they are just now coming into the light. Doug explains that the decriminalization in Oregon is a potential “pilot” of sorts, for the rest of the United States. Doug talks about the data that has been collected on psychedelic treatments lately and what we are learning about how these drugs work in ways we never even knew before including by opening up new connections and networks so that the brain is essence, healing itself. We discuss the comparison of the psychedelic space to the cannabis space and how they are quite the opposite of each other. Doug explains the long history of scientific research supporting the use of psychedelics spanning 4-5 decades.  Doug shares his hope that we will see a strong network of compassionate use programs or palliative care centers being developed in the future. People at the end of their life have anxiety and depression, so they could benefit greatly from the use of psychedelics during this particular journey. Finally, we discuss how the future of psychedelics look as investors. Doug advises to start looking beyond just psilocybin as the only molecule that can help people. There could be better compounds out there that we haven’t discovered yet because politics has dampened the growth in this space.   Connect with the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)  

#76 - Cybin CEO: Doug Drysdale on The Future of Psychedelic Treatments

In this mental health market update episode, we are covering valuation trends, investor sentiment, and our 9 key takeaways from the mental health startup market heading into 2021. We cover public and private market valuation trends impacting mental health startups, and we dig into results from a 150-investor survey we recently conducted on valuation expectations and market sentiment.  We also share our 9 key takeaways on the mental health startup market going into 2021 based on our 2020 experience investing $5.4mm dollars into 9 startups in the space at What If Ventures. Links Mentioned: Blog: Mental Health Investor Sentiment Survey: Extreme Optimism Going Into 2021 What If Fellowship:  https://whatif.vc/fellowship   Connect with the What If Ventures and the Stigma Podcast in the following ways: What If Fellowship, Patreon, Website, Twitter, Facebook, LinkedIn, Email Connect with host Stephen Hays here: Stephen Hays Personal Website, Twitter, LinkedIn, What If Ventures (Mental Health Venture Fund)

#75 - Mental Health Startup Valuation Trends and Investor Sentiment in 2021

We talk about mental health, addiction, and recovery. Our purpose is to reduce stigma by elevating the conversation on these topics. We interview people about their personal recovery, we talk to clinicians about mental health, illness and addiction and we talk to entrepreneurs building the next generation of solutions to help people achieve mental and emotional wellness. Our goal is to get people talking about mental health, the same way we talk about our physical health in order to reduce the stigma associated with mental illness and addiction.

hubhopper

Stigma Podcast - Mental Health

hubhopper